Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling
Abstract The discontinuation of denosumab [antibody targeting receptor activator of nuclear factor kappa B ligand (RANKL)] therapy may increase the risk of multiple vertebral fractures; however, the underlying pathophysiology is largely unknown. In patients who underwent discontinuation after multip...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-05-01
|
| Series: | Bone Research |
| Online Access: | https://doi.org/10.1038/s41413-025-00433-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|